This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock VACC vs. BIOA, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, PYRGF, and EGRXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), PyroGenesis Canada (PYRGF), and Eagle Pharmaceuticals (EGRX). Vaccitech vs. Its Competitors BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics PyroGenesis Canada Eagle Pharmaceuticals BioAge Labs (NASDAQ:BIOA) and Vaccitech (NASDAQ:VACC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Is BIOA or VACC more profitable? BioAge Labs has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A -25.39% -23.22% Vaccitech -409.18%-23.41%-20.85% Do institutionals & insiders have more ownership in BIOA or VACC? 26.1% of Vaccitech shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 6.0% of Vaccitech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to BIOA or VACC? In the previous week, BioAge Labs had 2 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Vaccitech. BioAge Labs' average media sentiment score of 0.00 equaled Vaccitech'saverage media sentiment score. Company Overall Sentiment BioAge Labs Neutral Vaccitech Neutral Which has better earnings & valuation, BIOA or VACC? Vaccitech has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AVaccitech$13.42M3.39$5.34M-$1.43-0.83 SummaryVaccitech beats BioAge Labs on 5 of the 8 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.49M$833.52M$5.82B$9.76BDividend YieldN/A4.84%4.40%4.04%P/E Ratio-0.831.1831.3826.05Price / Sales3.3926.35472.41122.40Price / Cash19.3019.5625.7828.78Price / Book0.186.579.526.07Net Income$5.34M-$5.54M$3.26B$265.39M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.18-0.4%N/A-0.8%$45.49M$13.42M-0.8333Gap UpBIOABioAge LabsN/A$4.44+0.5%N/AN/A$159.17MN/A0.00N/ACYBNCybin2.4181 of 5 stars$6.66+1.1%$85.00+1,176.1%N/A$157.32MN/A-1.5250News CoverageAnalyst RevisionVIRIVirios TherapeuticsN/A$4.81-9.2%$5.00+4.0%+2,250.8%$92.63MN/A-17.815Gap UpWHWKWhitehawk TherapeuticsN/A$1.65flatN/AN/A$77.76M$21.60M-27.5040High Trading VolumeOSTXOS Therapies2.3709 of 5 stars$2.22+3.3%$18.00+710.8%-40.2%$70.36MN/A-2.59N/AAnalyst ForecastELYMEliem TherapeuticsN/A$2.02-4.3%N/A-60.3%$60.10MN/A-3.819Positive NewsATNMActinium Pharmaceuticals2.4779 of 5 stars$1.63-1.2%$4.50+176.1%-13.4%$50.85MN/A-1.1730Positive NewsShort Interest ↓NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PYRGFPyroGenesis CanadaN/A$0.23+1.7%N/A-62.9%$43.60M$9.14M-3.8890Gap UpHigh Trading VolumeEGRXEagle Pharmaceuticals1.7235 of 5 stars$3.19+0.3%N/A-30.0%$41.43M$257.55M0.00100 Related Companies and Tools Related Companies BioAge Labs Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors PyroGenesis Canada Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access